[Federal Register Volume 72, Number 60 (Thursday, March 29, 2007)]
[Notices]
[Page 14832]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-5777]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a) authorizing the importation of such a
substance, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on January 5, 2007, Roche Diagnostics Operations, Inc., Attn:
Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of the basic classes of
controlled substances listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315).......... I
Alphamethadol (9605)....................... I
Tetrahydrocannabinols (7370)............... I
Cocaine (9041)............................. II
Ecgonine (9180)............................ II
Methadone (9250)........................... II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
the manufacture of diagnostic products for distribution to its
customers.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODL,
Washington, DC 20537; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than April 30, 2007.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import basic classes of any controlled substances
listed in schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: March 22, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-5777 Filed 3-28-07; 8:45 am]
BILLING CODE 4410-09-P